BIOCON News Today

Biocon Ltd Share Price

BIOCON

CMP as on 18-Apr-24 12:00
₹ 267

icon 3.45 | 1.31%

Open
₹ 272
Turnover(lac)
₹ 25,384
Prev. Close
₹ 263.75
Day's Vol (shares)
₹ 9,499,931
Day's Vol (shares)
₹ 265.80         ₹ 275.50

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Biocon joins hands with Biomm to commercialize diabetes drug in Brazil

Biomm's Nova Lima production facility is dedicated to the development, manufacture, and commercialization of complex biotech and biosimilar medicinal products.

  • 18 Apr, 2024 |
  • 11:06 AM
Image not found

Biocon's Liraglutide Approval Spurs Stock Rise, Eyes UK Market Expansion

The application for Liraglutide was filed by Biocon through its European partner, Zentiva.

  • 28 Mar, 2024 |
  • 3:02 PM
Image not found

Biocon Biologics slips ~6% after CFO Indranil Sen steps down

Indranil Sen has resigned to seek possibilities outside of the organisation.

  • 15 Mar, 2024 |
  • 2:28 PM
Image not found

Eris Lifesciences purchases Biocon Biologics’ domestic brand formulations biz

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

  • 15 Mar, 2024 |
  • 11:38 AM
Image not found

Biocon soars on US market entry deal with J&J

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

  • 01 Mar, 2024 |
  • 11:31 AM
Image not found

Biocon Faces ₹3 Crore Penalty Over GST-Related Issues, Plans Appeal

The penalty of ₹3,03,78,465 was imposed on February 22, 2024, by the Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalor

  • 26 Feb, 2024 |
  • 4:20 PM
Image not found

Biocon: FY25 to be another washout year

Recommendation: Reduce; Target price: ₹225

  • 12 Feb, 2024 |
  • 12:41 PM
Image not found

Biocon Soars with ₹660 Crore Net Profit in Q3, Driven by Strong Revenue Growth

The company's revenue from operations surged by 34.4% to ₹3,953.7 Crore compared to the previous year.

  • 09 Feb, 2024 |
  • 3:00 PM
Image not found

Biocon's Q3 Sees Robust Growth: Net Profit Soars to ₹660 Crore

The company's revenue from operations experienced robust growth, increasing by 34.4% to ₹3,953.7 Crore compared to the previous year

  • 09 Feb, 2024 |
  • 12:12 PM
Image not found

Biocon's cancer drug gets USFDA nod, but investors remain cautious

Biocon was trading on the BSE at ₹295.15 at 9:29 a.m., down ₹3.60, or 1.21 %.

  • 07 Feb, 2024 |
  • 11:16 AM